Open access peer-reviewed chapter

3-Hydroxy-3-Methylglutaryl-CoA Reductase (HMGR) Enzyme of the Sterol Biosynthetic Pathway: A Potential Target against Visceral Leishmaniasis

By Sushma Singh and N. Kishore Babu

Submitted: October 10th 2017Reviewed: February 15th 2018Published: October 10th 2018

DOI: 10.5772/intechopen.75480

Downloaded: 705


Sterol biosynthetic pathway is explored for its therapeutic potential for Visceral Leishmaniasis. In Leishmania, this pathway produces ergosterol which is absent in host and therefore is a promising strategy to combat proliferation of both extracellular and intracellular forms of the parasite with minimal host toxicity. The present chapter focuses on 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) enzyme which is the rate-limiting enzyme of the ergosterol biosynthesis. HMGR gene of L. donovani was biochemically and biophysically characterized for the first time. HMGR over expressing transgenic parasites were generated to evaluate its role in parasite growth and infection ability. A series of statins like atorvastatin, simvastatin and mevastatin were evaluated for its therapeutic efficacy and mode of action elucidated. Atorvastatin and mevastatin were found to be killing both the promastigote and amastigote forms of the parasite without exhibiting host cytotoxicity. Besides, non-statin class of molecules like resveratrol and glycyrrhizic acid were also analyzed for antileishmanial potential. Two antidepressants, ketanserin and mianserin were found to kill both L. donovani promastigotes and intracellular amastigotes with no apparent toxicity to the host cells. Since targeting of the sterol biosynthetic pathway enzymes may be useful therapeutically, the present work may have implications in treatment of Leishmaniasis.


  • Visceral Leishmaniasis
  • HMGR
  • ergosterol
  • statins
  • antidepressants

1. Introduction

A variety of Leishmaniaspecies are reported to cause disease, which afflicts about 12 million people in 98 countries of which Indian subcontinent, Sudan and Brazil are the major regions with higher incidence of Leishmaniasis. The World Health Organization (WHO) has considered Leishmaniasis to be one of the six priority diseases of its special programme for Research and Training in tropical diseases. Visceral Leishmaniasis (VL) being a neglected tropical disease has been of concern for several years. Antimonial compounds remain the first line drug for VL treatment with amphotericin B and pentamidine being the second line drugs. However, both the classes have high toxicity and serious side effects. Drug resistance, toxicity and long-term treatment profile are some of the issues which plague the treatment regimen. In the wake of this problem, there are increasing efforts to identify vaccine candidates and drug target candidates with equal focus on drug repositioning. Till date, several enzymes of various crucial metabolic pathways such as the pentose phosphate pathway, trypanothione biosynthesis pathway and sterol biosynthetic pathway have been explored in parasites [1]. With the whole genome sequence of Leishmania donovaninow available, it has become feasible to identify new genes and explore its essentiality in parasite survival and host infectivity. Structural analysis of identified enzymes would throw light on potential active site for designing pharmacophore. Based on this, in silicoligand screening is performed to identify potential compounds from already existing library. This would further lead to design and synthesis of new chemical entities whose potency can be evaluated in cell-based and target-based screening assays.

Sterol biosynthetic pathway is an important metabolic pathway in fungi and trypanosomatids. In recent years, attention has been focused on the sterol metabolism of Leishmaniaas a potential drug target for therapy. In sterol biosynthetic pathway, condensation of two acetyl-CoA units leads to formation of acetoacetyl-CoA, followed by the addition of a third unit to form 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA), which is further reduced by NADPH to produce mevalonic acid. The mevalonate pathway comprises of three steps and is catalyzed by acetoacetyl-CoA thiolase, and two mitochondrial enzymes HMG-CoA synthase and HMG-CoA reductase, in yeast [2] and in trypanosomatids [3]. Sterols are important components of the cell membrane that are important for cellular function and maintenance of cell structure. Unlike mammalian cells which have cholesterol as the major membrane sterol, trypanosomatids synthesize ergosterol and other 24-methyl sterols that are required for their growth and viability. Leishmaniaparasite contains predominantly ergostane-based sterols such as ergosterol, which differ from cholesterol by the presence of a 24-methyl group at Δ7 and Δ22 bonds [4]. Therefore, the sterol biosynthetic pathway from Leishmaniais considered to be an important drug target. Squalene synthase (SQS) catalyzes the first committed step of sterol synthesis by coupling two farnesyl molecules to form squalene. Two quinuclidine derivatives, ER-119884 and E5700, have been shown to be potent antileishmanial and anti-trypanosomal agents. The inhibition of SQS by these compounds decreased endogenous sterol levels of the parasite and caused an anti-proliferative effect on the parasite [5]. Sterol 24-C-methyltranferase (SMT) is unique to the parasite and validated as a potential drug target against trypanosomatid parasites. Azosterols like ketoconazole are known to inhibit SMT in fungi. They were also found to be anti-proliferative in Leishmania amazonensis[6].

One of the enzymes of the sterol biosynthetic pathway which is focused in this chapter is 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR, EC: HMGR catalyzes the NADPH dependent synthesis of mevalonate from HMG-CoA and is a rate limiting step [7]. There are two classes of HMG-CoA reductase: class I (eukaryotic HMGRs) and class II (prokaryotic HMGRs). The class I HMGR has an N-terminal membrane domain and is present in eukaryotes and several archaea. Class II HMGR lacks this domain and occurs in Pseudomonas mevalonii, Archaeoglobus fulgidus, Staphylococcus aureus, Enterococcus faecalisand Streptomycetes[8, 9, 10, 11]. L. majorHMGR enzyme lacks the N-terminal domain and is the only eukaryote with soluble HMGR protein. Among kinetoplastids, HMGR has been earlier characterized in L. majorand Trypanosoma cruzi[12, 13]. Given that ergosterol is an important component of Leishmaniamembrane, we focused our research on identification and validation of HMGR from L. donovanias a potential drug target candidate.

L. donovaniHMGR gene was identified via a BLAST search of the genome using L. majorHMGR sequence ( as the template. LdHMGR gene was amplified, cloned in pET30a (+) vector and sequenced (GenBank accession no. JX036280.1). LdHMGR exhibited only 25.2% identity (35% similarity) with human HMGR. This signifies that host HMGR is significantly different from parasite HMGR. HMGR enzyme is constitutively expressed in Leishmaniapromastigotes as shown by western blot analysis [14, 27].

1.1. Functional analysis of LdHMGR overexpressors

Next, we were interested to see whether HMGR has any role in parasite growth and infectivity. For this, HMGR was cloned in a Leishmaniaspecific overexpression vector. HMGR overexpression in L. donovanipromastigotes was confirmed by measuring of HMGR activity, estimation of ergosterol levels and western blot analysis confirmed the overexpression of HMGR gene [15].

1.2. Growth curve analysis of HMGR transfectants

The growth profile of transfected and wild-type parasites in vitrowas studied by measuring OD at 600 nm of the plated cells for every 24 h. We monitored the growth of parasites and LdHMGR transfectants exhibited ~ 1.5 fold increase in growth than compared to wild-type and psp vector transfected parasites (Figure 1A).

Figure 1.

Functional analysis ofLdHMGR overexpressors. (A) Growth analysis of wild-type (WT), psp andLdHMGR overexpressing parasites; (B) evaluation of infection efficiency of wild-type (WT), psp andLdHMGR overexpressors. Data were expressed as mean ± standard deviations from three independent experiments. *p ≤ 0.05.

1.3. Role of HMGR in parasite infection ability

The transfectants were tested for their ability to infect THP-1 differentiated macrophages. The stationary phase of wild-type and HMGR overexpressing promastigotes were used to infect THP-1 differentiated macrophages. The percentage of infection with wild type was considered as 100% and relatively percentage of infection was calculated for psp and HMGR overexpressors. The HMGR transfectants exhibited ~2 fold change in the infectivity compared to wild-type parasites (Figure 1B).

In other organisms like yeast, it was reported that combined overexpression of genes (ERG1and ERG11) leads to significant increase in the amount of total sterols by threefold in comparison with a wild-type strain in yeast. The HMG-CoA reductase controls the entering of intermediates on the pre-squalene part of the pathway and Erg1p and Erg11p seem to control the transfer of intermediates into the post-squalene part of sterol biosynthetic pathway [16]. Other studies reported that overexpression of HMGR in yeast leads to increased linalool production which is a plant monoterpene which display antiparasitic, antimicrobial and antiviral properties as well as a plethora of promising health benefits [17].


2. HMGR inhibition profiles

2.1. Evaluation of antileishmanial effect of class I statin (simvastatin), class II statin (atorvastatin) and mevastatin

The inhibitors used in the present study were atorvastatin, simvastatin and mevastatin. The concentrations of atorvastatin and mevastatin at which 50% growth of L. donovanipromastigotes was inhibited (IC50) were 19.4 ± 3.07 μM and 23.8 ± 4.2 μM respectively [14, 18, 25]. The IC50 value of simvastatin was 73.2 ± 3.7 μM and at 100 μM it caused only 63% inhibition. The cytotoxicity of atorvastatin, simvastatin and mevastatin against THP-1 differentiated macrophages was determined by using MTT assay. The IC50 value of three drugs were found to be above 100 μM, that is, noncytotoxic to host macrophage cell line. Miltefosine inhibited promastigote growth with an IC50 value of 14.6 μM. Atorvastatin was found to inhibit L. donovanipromastigotes at low micromolar concentrations compared to mevastatin and simvastatin. The concentrations of atorvastatin, simvastatin and mevastatin at which 50% growth of L. donovani amastigotes was inhibited (IC50) were 6.75 ± 0.353 μM, 21.5 ± 4.94 μM and 7.5 ± 1.1 μM respectively. The amastigotes were approximately threefold more sensitive to atorvastatin and resveratrol than promastigotes. Miltefosine was taken as the reference drug, and its IC50 value for amastigotes was 3.9 ± 1.27 [14, 25]. The IC50 values are depicted in Table 1.

InhibitorsIC50 values (μM)
L. donovanipromastigotesL. donovaniamastigotesTHP-1 differentiated macrophagesSI valuesrHMGR
Atorvastatina19.4 ± 3.076.75 ± 0.353>100>14.80.315 ± 2.12
Simvastatina73.2 ± 3.721.5 ± 4.94>100>4.6543.66 ± 31.5
Mevastatina23.8 ± 4.27.5 ± 1.1>100>13.342.2 ± 3.0
Miltefosineb14.6 ± 1.73.9 ± 1.2743.6 ± 5.511.17

Table 1.

Antileishmanial effect of statins.

Dinesh et al. [14, 25].

Dinesh et al. [18].

The inhibitors were screened for their ability to inhibit the catalytic efficiency of recombinant LdHMGR. The IC50 value of atorvastatin, simvastatin and mevastatin was found to be half maximal at around 315 ± 2.12 nM, 43.66 ± 31.5 μM and 42.2 ± 3.0 μM respectively. Atorvastatin (1 μM) resulted in 93.5 ± 7.2% inhibition of the recombinant HMGR. Table 1 shows the IC50 values of the statins on recombinant HMGR.

2.2. Evaluation of antidepressants as HMGR inhibitors

Tricyclic drugs, antidepressants and antipsychotics are reported to be toxic to both the promastigote and amastigote forms of Leishmania[19]. Imipramine, a tricyclic antidepressant belonging to the same class of cationic amphiphilic drugs, when administered orally was found to be active against both antimony-sensitive and antimony resistant clinical isolates of L. donovani[20].

Ketanserin is a serotonin S2-receptor antagonist which is used as an antihypertensive agent. The IC50 value of ketanserin for L. donovanipromastigotes was 37.8 μM and intracellular amastigotes was 28.5 μM. It was however found to be noncytotoxic up to a concentration of 100 μM, when tested on differentiated THP-1 cells. Miltefosine inhibited amastigote growth with an IC50 value of 3.4 μM which correlated with the previously reported data [21]. However, the standard drug killed the macrophage cells at an IC50 value of 43.6 μM. This was well correlated with the already published results on the effect of miltefosine on THP-1 and J774A.1 cell line [22, 23]. These results showed that ketanserin displayed antileishmanial activity at noncytotoxic concentrations. We evaluated the effect of ketanserin on recombinant LdHMGR and found its IC50 value to be 43 ± 2.5 μM. This data showed that ketanserin binds to the LdHMGR enzyme active site and inhibits its activity (Table 2) [15].

InhibitorsIC50 values (μM)
L. donovanipromastigotesL. donovaniamastigotesTHP-1 differentiated macrophagesSI valuesrHMGR
Mianserina21.0 ± 3.746.4 ± 5.2>100>2.1519.8 ± 3.1
Ketanserinb37.8 ± 3.328.5 ± 1.9>100>3.543.0 ± 2.5
Miltefosinea14.6 ± 1.73.4 ± 0.943.6 ± 5.512.8

Table 2.

Antileishmanial effect of antidepressants.

Dinesh et al. [14, 25].

Singh et al. [15].

Mianserin hydrochloride is a noradrenergic and specific serotonergic antidepressant (NaSSA) with a tetracyclic structure and is used for the treatment of depressive illness and depression associated with anxiety [24]. Mianserin strongly blocks postsynaptic 5-HT2 receptors and only weakly blocks post synaptic 5-HT1 and 5-HT3 receptors and blocks moderately presynaptic α2 receptors [24]. The effect of mianserin was investigated on the proliferation rate of L. donovanipromastigotes and amastigotes. The dose-dependent antileishmanial effect of mianserin against L. donovanipromastigotes resulted in significant reduction in viable parasites compared to the untreated parasites. The concentration of mianserin at which 50% of the promastigote and amastigote growth was inhibited was 21 ± 3.7 μM and 46.4 ± 5.2 μM respectively. Mianserin up to 100 μM failed to cause any toxic effect on viability of THP-1 differentiated macrophages indicating that mianserin selectively inhibits Leishmaniapromastigotes. Mianserin inhibited recombinant L. donovaniHMGR enzyme with an IC50 value of 19.8 ± 3.1 μM (Table 2) [14, 25].


3. Natural products as inhibitors of HMGR

The inhibitors used in the present study were resveratrol and glycyrrhizic acid. The concentrations of resveratrol at which 50% growth of L. donovanipromastigotes was inhibited (IC50) was 36.1 ± 3.6 μM. The cytotoxicity of resveratrol against THP-1 differentiated macrophages was determined by using MTT assay. The results showed the IC50 value of three drugs was found to be above 100 μM, that is, noncytotoxic to host macrophage cell line. The concentrations of resveratrol at which 50% growth of L. donovaniamastigotes was inhibited IC50 value was 9.5 ± 2.12 μM [14, 25]. The data are depicted in Table 3.

InhibitorsIC50 values (μM)
L. donovanipromastigotesL. donovaniamastigotesTHP-1 differentiated macrophagesSI valuesrHMGR
Glycyrrhizic acida34.0 ± 2.920.0 ± 4.24>100>5.024.0 ± 4.3
Resveratrolb36.1 ± 3.69.5 ± 2.12>100>10.546.3 ± 16.4
Miltefosinea15.3 ± 2.13.8 ± 1.244.2 ± 5.2911.5

Table 3.

Natural products as inhibitors of HMGR.

Dinesh et al. [28].

Dinesh et al. [14, 25].

Glycyrrhiza glabra, which is popularly known as liquorice is used for the treatment of pulmonary diseases and inflammatory processes [26]. Glycyrrhizic acid (GA), licochalone A and Glycyrrhetinic acid which have been reported to exert antileishmanial properties are the major bioactive components in liquorice root [27, 29, 30]. GA exhibits potent antileishmanial and immunomodulatory properties with enhanced parasite clearance [27]. A dose-dependent inhibition of the viability of L. donovanipromastigotes was observed in the presence of GA. The IC50 determined from the graph was approximately 34 ± 2.9 μM. GA was found to inhibit intracellular amastigotes with an IC50 value of 20 ± 4.2 μM. GA did not cause macrophage killing up to 100 μM concentration. GA was tested against recombinant LdHMGR enzyme at the range of 10–100 μM concentration. The IC50 value was found to be 24 ± 4.3 μM (Table 3).

In Leishmaniasterol, biosynthetic pathway produces ergosterol which is absent in host. This makes LdHMGR enzyme a potential drug target for designing parasite specific molecules. The present review encompasses functional characterization of L. donovaniHMGR enzyme and the evaluation of the effect of various HMGR inhibitors as potential candidates for treatment of Leishmaniasis. Inhibitors which showed inhibition of both the extracellular and intracellular forms of the parasites at low micromolar range with no cytotoxicity to host cells are promising antileishmanial candidates. They can be further explored in an experimental animal model of VL to evaluate its anti-VL efficacy.

© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution 3.0 License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite and reference

Link to this chapter Copy to clipboard

Cite this chapter Copy to clipboard

Sushma Singh and N. Kishore Babu (October 10th 2018). 3-Hydroxy-3-Methylglutaryl-CoA Reductase (HMGR) Enzyme of the Sterol Biosynthetic Pathway: A Potential Target against Visceral Leishmaniasis, Leishmaniases as Re-emerging Diseases, Farhat Afrin and Hassan Hemeg, IntechOpen, DOI: 10.5772/intechopen.75480. Available from:

chapter statistics

705total chapter downloads

2Crossref citations

More statistics for editors and authors

Login to your personal dashboard for more detailed statistics on your publications.

Access personal reporting

Related Content

This Book

Next chapter

Alternative Treatment for Leishmaniasis

By Renata Mondêgo de Oliveira, Solange de Araújo Melo, Tatiane Aranha da Penha-Silva, Fernando Almeida-Souza and Ana Lucia Abreu-Silva

Related Book

First chapter

Cocoon Strategy of Vaccinations: Benefits and Limitations

By Aneta Nitsch-Osuch

We are IntechOpen, the world's leading publisher of Open Access books. Built by scientists, for scientists. Our readership spans scientists, professors, researchers, librarians, and students, as well as business professionals. We share our knowledge and peer-reveiwed research papers with libraries, scientific and engineering societies, and also work with corporate R&D departments and government entities.

More About Us